Combining Januvia (Sitagliptin) and Jardiance (Empagliflozin)
Januvia and Jardiance can be safely combined without dose adjustments, and this combination is highly effective for type 2 diabetes management, particularly when metformin alone is insufficient. 1, 2
Dosing Recommendations
Standard Dosing
- Januvia (sitagliptin): 100 mg once daily, with or without food 1
- Jardiance (empagliflozin): Standard doses are 10 mg or 25 mg once daily
- No pharmacokinetic interactions: These medications can be coadministered without dose adjustments for either drug 2
Renal Function-Based Dosing for Januvia
Critical: Assess renal function before initiating Januvia and periodically thereafter 1
| Renal Function | CrCl | Januvia Dose |
|---|---|---|
| Mild impairment | ≥50 mL/min | 100 mg once daily (no adjustment) |
| Moderate impairment | 30 to <50 mL/min | 50 mg once daily |
| Severe impairment/ESRD | <30 mL/min or dialysis | 25 mg once daily |
Jardiance Renal Considerations
- Glucose-lowering effect minimal at eGFR <45 mL/min 3
- Continue for cardiovascular and kidney benefits until dialysis or transplantation even when glucose-lowering effect diminishes 3
- No dose adjustment required for Jardiance based on renal function 3
Clinical Efficacy
Adding empagliflozin to patients already on metformin and sitagliptin produces superior glycemic control compared to continuing sitagliptin alone. 4 In a phase 3 trial, empagliflozin 10 mg or 25 mg added to metformin + sitagliptin reduced HbA1c by 0.7-0.8% more than placebo at 24 weeks (p <0.0001) 4.
When comparing the two drugs head-to-head as add-ons to metformin, empagliflozin demonstrates superior outcomes: 5
- Greater HbA1c reduction
- More body weight loss (2-3 kg more than sitagliptin) 6, 5
- Better systolic and diastolic blood pressure reduction 6, 5
- Improved fasting plasma glucose control 4
The combination is more potent than either monotherapy, with no increased hypoglycemia risk since neither drug causes hypoglycemia independently 7.
Monitoring Requirements
Before Initiation
- Renal function assessment (serum creatinine, calculate CrCl using Cockcroft-Gault formula) 1
- Baseline HbA1c, fasting glucose
- Blood pressure and weight
Ongoing Monitoring
- Periodic renal function assessment (particularly important for Januvia dosing) 1
- Volume status and blood pressure (for Jardiance) 3
- Signs/symptoms of genital mycotic infections (significantly higher with empagliflozin) 5
- Urinary tract infection symptoms
- Vitamin B12 levels if on metformin 3
Safety Considerations and Adverse Effects
Januvia-Specific Warnings
- Pancreatitis: Discontinue promptly if suspected 1
- Hypersensitivity reactions: Including anaphylaxis, angioedema, Stevens-Johnson syndrome 1
- When combined with insulin or sulfonylureas: Lower doses of these agents may be needed to reduce hypoglycemia risk 1
Jardiance-Specific Warnings
- Genital mycotic infections: Most common adverse effect; mitigate with genital hygiene 3, 5
- DKA risk: Rare in T2DM but discontinue 3-4 days before surgery, during critical illness, or prolonged fasting 3
- Volume depletion: Monitor volume status and blood pressure, especially when ill or fasting 3
- Fournier's gangrene: Rare but requires prompt treatment if suspected 3
- Increased urination frequency: Expected effect (HR 4.05) 8
Combination Safety Profile
The combination is well-tolerated with no drug-drug interactions. 2 In pharmacokinetic studies, coadministration showed no clinically relevant changes in drug exposure (AUC or Cmax) for either medication 2. Adverse event rates were similar to monotherapy, with no additional safety signals during combination therapy 2.
Practical Algorithm for Use
- Assess renal function first → Adjust Januvia dose accordingly
- Start both medications at standard doses (no interaction concerns)
- If patient already on metformin + sitagliptin with inadequate control → Add empagliflozin 10 mg, can increase to 25 mg 4
- Monitor for genital infections in first 3 months (empagliflozin effect)
- Reassess renal function periodically → Adjust Januvia if CrCl declines
- Continue empagliflozin even if eGFR <45 mL/min for cardiovascular/renal benefits 3
Key Clinical Advantages
According to 2025 ADA guidelines, SGLT2 inhibitors (like Jardiance) provide proven benefits for cardiovascular outcomes, heart failure, and chronic kidney disease 3, while DPP-4 inhibitors (like Januvia) are neutral for these outcomes 3. This makes empagliflozin the preferred add-on agent when considering long-term morbidity and mortality, though the combination can be used when both mechanisms are desired for glycemic control.
Real-world evidence suggests empagliflozin offers renoprotective benefits compared to sitagliptin with slower eGFR decline over time 8, though serum phosphorus levels may increase and warrant monitoring 8.